Uproleselan Combo Does Not Improve EFS Vs Chemo in Newly Diagnosed AML
Investigators will present topline data from the phase 2/3 study of uproleselan/chemotherapy at a future medical meeting.
Empowering Awareness to Address Rising Gynecological Cancer Incidence
Ginger J. Gardner, MD, FACOG, highlights disease prevention innovations and other ongoing efforts to empower education in the gynecologic cancer field.
Vascular biomarkers reveal a unique toxicity profile of posttransplant cyclophosphamide: secondary analysis of BMT CTN 0402 and 1202
Posttransplant cyclophosphamide leads to unique changes in vascular biomarkers, revealing a distinct toxicity profile compared to other GVHD prophylaxis regimens.
Leveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic Diseases
A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.
Letter from Rigel Points to New Safety Signal of Pralsetinib in RET+ NSCLC
Data from the AcceleRET-Lung trial show an imbalanced risk of severe and fatal infection with pralsetinib for patients with RET fusion-positive NSCLC.
FDA Grants Accelerated Approval to Asciminib in Ph+ CML in Chronic Phase
Data from the ASC4FIRST trial support the accelerated approval of asciminib in this CML population.
